Cover Image
市場調查報告書

美國的抗憂鬱劑市場預測

Antidepressant Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 323536
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
美國的抗憂鬱劑市場預測 Antidepressant Market in the US 2015-2019
出版日期: 2015年01月28日 內容資訊: 英文 104 Pages
簡介

根據美國CDC(疾病預防管理中心)的實況報導,國內10人有1人患有憂鬱症。重度憂鬱症性障礙是消耗性大的障礙之一,根據NIMH(國立精神衛生研究所),國內18歲以上的成人人口裡面,大約有1,480萬人患病。從2014年到2019年,美國的抗憂鬱劑市場以4.08%的年複合成長率擴大。

本報告提供美國的抗憂鬱劑市場相關調查、主要產品簡介、疾病概要、治療及管理法、市場規模的變化與預測、影響市場成長因素分析、供應商及主要藥物的競爭分析、主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Celexa
  • Fetzima
  • Lexapro
  • Viibryd
  • Cymbalta
  • Prozac
  • Symbyax
  • Paxil
  • Wellbutrin
  • Abilify
  • Effexor
  • Pristiq
  • Zoloft

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 疾病概要

  • 憂鬱症和那個類型
    • 重度憂鬱症性障礙
    • 持續性抑鬱症疾病
    • 心因性憂鬱症
    • 產後憂鬱症
    • 季節性感情障礙
    • 躁鬱症
  • 病因
  • 流行病學
    • 成人的躁鬱症
    • 成人的神經官能性憂鬱障礙
    • 成人的重度憂鬱症
    • 青年時期的重度憂鬱症
  • 治療和管理
  • 經濟負擔

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各作用機制市場

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • 主要藥物的競爭分析
    • Eli Lilly
    • Otsuka Pharmaceutical
    • Pfizer
    • GlaxoSmithKline
    • Actavis
  • 其他卓越供應商

第18章 主要供應商分析

  • Actavis
  • Eli Lilly
  • GlaxoSmithKline
  • Otsuka Pharmaceutical
  • Pfizer
    • 主要資料
    • 產業概要
    • 各產業分類收益
    • 各地區收益
    • 產業策略
    • 主要的發展趨勢
    • SWOT分析

第19章 相關報告

圖表

目錄
Product Code: IRTNTR5038

About Depression

According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Depression can be recurrent, and can be severely debilitating for an individual. In patients with mild depression, the patient can be treated with medications, and in moderate or severe depression, a patient needs both medication and professional psychotherapy in terms of counseling. It has been reported by the WHO in 2008, that depression equally affects men and women, but women have a 50 percent higher tendency to get affected by depression than men. According to the CDC, depression can lead to adverse behavioral traits in an individual such as, alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, one out of every 10 people is affected with depression in the US. Major depressive disorder is among the most debilitating disorders in the US, and affects approximately 14.8 million adults in the country, aged 18 years and above, according to the NIMH in the US.

TechNavio's analysts forecast the Antidepressant market in the US to grow at a CAGR of [4.08] percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Antidepressant market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of depression. The Antidepressant market in the US is segmented based on the mechanism of action of the drugs used to treat depression, as illustrated below:

  • Tricyclic Antidepressants
  • Serotonin Norepinephrine Reuptake Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Monoamine Oxidase Inhibitors
  • Others

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Antidepressant market in the US. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Antidepressant Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Antidepressant market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Actavis
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Otsuka Pharmaceutical
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • AstraZeneca
  • Aurobindo Pharma
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories
  • H. Lundbeck
  • Janssen Pharmaceuticals
  • Lupin
  • Novartis
  • Pierre Fabre
  • Shire
  • Somerset Pharmaceuticals
  • Sun Pharmaceutical
  • Sunovion Pharmaceuticals
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Torrent Pharmaceuticals
  • Valeant Pharmaceuticals

Market Driver

  • Rise in Patient Population
  • For a full, detailed list, view our report

Market Challenge

  • Threat from Patent Expiries
  • For a full, detailed list, view our report

Market Trend

  • Growing Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Celexa
    • 04.1.2. Fetzima
    • 04.1.3. Lexapro
    • 04.1.4. Viibryd
    • 04.1.5. Cymbalta
    • 04.1.6. Prozac
    • 04.1.7. Symbyax
    • 04.1.8. Paxil
    • 04.1.9. Wellbutrin
    • 04.1.10. Abilify
    • 04.1.11. Effexor
    • 04.1.12. Pristiq
    • 04.1.13. Zoloft

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disorder Overview

  • 07.1. Depression & its Types
    • 07.1.1. Major Depressive Disorder
    • 07.1.2. Persistent Depressive Disorder
    • 07.1.3. Psychotic Depression
    • 07.1.4. Post-partum Depression
    • 07.1.5. Seasonal Affective Disorder
    • 07.1.6. Bipolar Disorder
  • 07.2. Etiology
  • 07.3. Epidemiology
    • 07.3.1. Bipolar Disorder Among Adults
    • 07.3.2. Dysthymic Disorder Among Adults
    • 07.3.3. Major Depression Among Adults
    • 07.3.4. Major Depression Among Adolescents
  • 07.4. Treatment & Management
  • 07.5. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Mechanism of Action

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Competitive Assessment of the Top Drugs for Depression
    • 17.2.2. Eli Lilly
    • 17.2.3. Otsuka Pharmaceutical
    • 17.2.4. Pfizer
    • 17.2.5. GlaxoSmithKline
    • 17.2.6. Actavis
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Actavis
    • 18.1.1. Key Facts
    • 18.1.2. Business Description
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Information
    • 18.1.8. SWOT Analysis
  • 18.2. Eli Lilly
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation by Revenue
    • 18.2.4. Sales by Geography
    • 18.2.5. Business Strategy
    • 18.2.6. Key Information
    • 18.2.7. SWOT Analysis
  • 18.3. GlaxoSmithKline
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Pipeline Products
    • 18.3.7. Business Strategy
    • 18.3.8. Key Information
    • 18.3.9. SWOT Analysis
  • 18.4. Otsuka Pharmaceutical
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2014
    • 18.4.4. Business Segmentation by Revenue 2013 and 2014
    • 18.4.5. Geographical Segmentation by Revenue 2014
    • 18.4.6. Business Strategy
    • 18.4.7. Recent Developments
    • 18.4.8. SWOT Analysis
  • 18.5. Pfizer
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation by Revenue 2013
    • 18.5.4. Business Segmentation by Revenue 2012 and 2013
    • 18.5.5. Geographical Segmentation by Revenue
    • 18.5.6. Business Strategy
    • 18.5.7. Key Developments
    • 18.5.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: NIMH Classification of Depression
  • Exhibit 3: Prevalence Data for Major Depressive Disorder Episodes in US Adults (2012)
  • Exhibit 4: Prevalence Data for Dysthymic Disorder Episodes in US Adults (2012)
  • Exhibit 5: Prevalence Data for Major Depressive Disorder Episodes according to the Severe Impairment Episodes in US Adults (2012)
  • Exhibit 6: Prevalence Data for Major Depressive Disorder Episodes in US Adults (2012)
  • Exhibit 7: Prevalence Data for Major Depression Among Adults in US (2012)
  • Exhibit 8: Management of Depression According to the WHO Guidelines
  • Exhibit 9: Economic Burden of Depression in the US
  • Exhibit 10: A Break-up of the Costs Associated with Depression
  • Exhibit 11: Snapshot of the Economic Burden of Depression in the US
  • Exhibit 12: Antidepressant Market in the US 2014-2019 (US$ million)
  • Exhibit 13: Drivers and Challenges of the Antidepressant Market in the US
  • Exhibit 14: Antidepressant Market in the US Segmentation by Mechanism of Action
  • Exhibit 15: Antidepressants Market in the US Segmentation by Mechanism of Action
  • Exhibit 16: Buying Criteria of the Antidepressant Market in the US
  • Exhibit 17: Drivers and their Impact on the Key Customer Category of the Antidepressant Market in the US
  • Exhibit 18: Antidepressant Market in the US Market Share Analysis 2014
  • Exhibit 19: Revenue Comparison of Top Drugs for Depression in 2013 (US$ million)
  • Exhibit 20: YoY Revenue of Cymbalta in the US 2010-2013 (US$ million)
  • Exhibit 21: YoY Global Revenue of Cymbalta 2010-2013 (US$ million)
  • Exhibit 22: YoY Revenue of Abilify (in the US, the UK, Germany, Spain, France, Italy and some other European countries) 2010-2013 (US$ million)
  • Exhibit 23: YoY Global Revenue of Pristiq 2010-2013 (US$ million)
  • Exhibit 24: YoY Global Revenue of Zoloft 2010-2013 (US$ million)
  • Exhibit 25: YoY Global Revenue of Effexor 2010-2013 (US$ million)
  • Exhibit 26: YoY Revenue of Wellbutrin in the US 2010-2013 (US$ million)
  • Exhibit 27: YoY Global Revenue of Wellbutrin 2010-2013 (US$ million)
  • Exhibit 28: YoY Global Revenue of Paxil 2010-2014 (US$ million)
  • Exhibit 29: Actavis: Business Segmentation 2013
  • Exhibit 30: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 31: Actavis : Sales by Geography (in US$ million)
  • Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 34: Eli Lilly: Sales by Geography 2013
  • Exhibit 35: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 36: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 37: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 38: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 39: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
  • Exhibit 40: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 41: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
  • Exhibit 42: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 43: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 44: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top